Pictet & Cie Europe SA Sells 117 Shares of Eli Lilly and Company (NYSE:LLY)

Pictet & Cie Europe SA reduced its stake in Eli Lilly and Company (NYSE:LLY) by 4.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,447 shares of the company’s stock after selling 117 shares during the quarter. Pictet & Cie Europe SA’s holdings in Eli Lilly and were worth $565,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. Amundi bought a new position in shares of Eli Lilly and during the second quarter worth approximately $1,008,577,000. Jennison Associates LLC increased its holdings in shares of Eli Lilly and by 63.8% during the second quarter. Jennison Associates LLC now owns 8,910,995 shares of the company’s stock worth $2,045,252,000 after purchasing an additional 3,470,858 shares during the period. BlackRock Inc. increased its holdings in shares of Eli Lilly and by 3.1% during the second quarter. BlackRock Inc. now owns 60,927,657 shares of the company’s stock worth $13,984,117,000 after purchasing an additional 1,856,395 shares during the period. AMF Pensionsforsakring AB bought a new position in shares of Eli Lilly and during the second quarter worth approximately $240,526,000. Finally, Macquarie Group Ltd. increased its holdings in shares of Eli Lilly and by 190.4% during the second quarter. Macquarie Group Ltd. now owns 1,237,698 shares of the company’s stock worth $284,079,000 after purchasing an additional 811,525 shares during the period. 81.79% of the stock is currently owned by institutional investors.

NYSE LLY opened at $249.52 on Friday. The company’s 50 day moving average is $260.85 and its 200-day moving average is $250.57. Eli Lilly and Company has a 12-month low of $178.58 and a 12-month high of $283.90. The company has a quick ratio of 1.02, a current ratio of 1.30 and a debt-to-equity ratio of 1.95. The firm has a market cap of $238.69 billion, a P/E ratio of 38.06, a price-to-earnings-growth ratio of 1.91 and a beta of 0.36.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Monday, October 25th. The company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.98 by ($0.04). The business had revenue of $6.77 billion during the quarter, compared to the consensus estimate of $6.64 billion. Eli Lilly and had a net margin of 21.52% and a return on equity of 111.51%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the firm earned $1.54 EPS. Equities analysts expect that Eli Lilly and Company will post 8.18 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 10th. Investors of record on Tuesday, February 15th will be issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a yield of 1.57%. The ex-dividend date is Monday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.85. Eli Lilly and’s dividend payout ratio is 51.83%.

Several analysts recently issued reports on LLY shares. Wells Fargo & Company increased their price target on shares of Eli Lilly and from $270.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 4th. BMO Capital Markets raised their target price on shares of Eli Lilly and from $311.00 to $320.00 and gave the company an “outperform” rating in a research report on Thursday, December 16th. Truist raised their target price on shares of Eli Lilly and from $262.00 to $301.00 and gave the company a “buy” rating in a research report on Wednesday, November 24th. JPMorgan Chase & Co. restated a “buy” rating on shares of Eli Lilly and in a research report on Thursday, December 16th. Finally, Truist Securities raised their target price on shares of Eli Lilly and from $262.00 to $301.00 and gave the company a “buy” rating in a research report on Wednesday, November 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $287.74.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 3,570 shares of the business’s stock in a transaction that occurred on Monday, December 27th. The shares were sold at an average price of $279.53, for a total value of $997,922.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders sold 424,939 shares of company stock valued at $114,549,362. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Further Reading: What are gap-up stocks?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.